If (FITX) had less shares it would be trading equally higher than it is now, that we know. But even with the amount of shares we have its still highly undervalued based on the prospective annual revenue. We aren't even trading at 1% of our prospected revenue.

CEN Biotech will be fine and Bill's hinted at buyback options.